Second Primary Cancers in Melanoma Patients Critically Shorten Survival

Show full item record



Zheng , G , Chattopadhyay , S , Sundquist , K , Sundquist , J , Försti , A , Hemminki , A & Hemminki , K 2020 , ' Second Primary Cancers in Melanoma Patients Critically Shorten Survival ' , Clinical Epidemiology , vol. 12 , pp. 105-112 .

Title: Second Primary Cancers in Melanoma Patients Critically Shorten Survival
Author: Zheng, Guoqiao; Chattopadhyay, Subhayan; Sundquist, Kristina; Sundquist, Jan; Försti, Asta; Hemminki, Akseli; Hemminki, Kari
Contributor organization: Department of Oncology
HUS Comprehensive Cancer Center
Research Programs Unit
TRIMM - Translational Immunology Research Program
University of Helsinki
Date: 2020
Language: eng
Number of pages: 8
Belongs to series: Clinical Epidemiology
ISSN: 1179-1349
Abstract: Background: Survival in malignant cutaneous melanoma has improved but increasing survival will result in an increased likelihood of the occurrence of second primary cancers (SPCs). SPCs may adversely interfere with survival. We quantified survival in patients with different types of SPCs, in comparison to known poor prognostic indicators of metastatic disease. Methods: Data for melanoma and any SPCs were obtained from the Swedish Cancer Registry for years 2003 through 2015, including clinical TNM classification. SPCs were grouped into three 'prognostic groups' based on 5-year relative survival of these cancers as first primary cancer. Kaplan-Meier survival curves were generated and hazard ratios were estimated using Cox regression, adjusted for a number of variables and treating diagnosis of SPC as a time-dependent variable. Results: The total number of first melanoma patients was 28,716 followed by 3,202 (11.1%) SPCs, 1/3 of which had a second melanoma while 2/3 had other SPCs. Among men diagnosed at age over 70 years, who survived at least 10 years, 31.4% had SPC. HRs (95% CI) for survival increased systematically from the reference rate of 1.00 (no SPC) to 1.59 (1.35-1.87) with SPC of good prognosis (78.6% of SPCs) to 3.49 (2.58-4.72) of moderate prognosis (12.0%) and to 7.93 (5.50-11.44) of poor prognosis (9.4%). In patients without SPC, the HRs increased to 2.62 (2.02-3.39) with any nodal metastases and to 5.88 (4.57-7.57) with any distant metastases compared to patients without local or distant metastases. Conclusion: The data showed that SPCs are an increasingly common negative prognostic factor for melanoma. Future attempts to improve melanoma survival need to target SPCs.
Subject: melanoma
second cancer
3142 Public health care science, environmental and occupational health
3122 Cancers
Peer reviewed: Yes
Rights: cc_by_nc
Usage restriction: openAccess
Self-archived version: publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
clep_230149_sec ... ients_critically_short.pdf 1.409Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record